Biological studies of iron chelating agent KN1 and cobalt containing complex KNK 0.1 as hypoxia-activated anticancer prodrugs
| dc.contributor.advisor | Sipos, Éva | |
| dc.contributor.advisordept | Gyógyszerésztudományi Kar::Gyógyszerhatástani Tanszék | |
| dc.contributor.author | Phan Trung, Phuong | |
| dc.contributor.department | DE--Gyógyszerésztudományi Kar | |
| dc.contributor.opponent | Pető, Ágota | |
| dc.contributor.opponent | Homolya, Ágnes | |
| dc.contributor.opponentdept | Gyógyszerésztudományi Kar | |
| dc.contributor.opponentdept | Gyógyszerésztudományi Kar::Gyógyszerészi Kémiai Tanszék | |
| dc.date.accessioned | 2026-04-16T10:27:10Z | |
| dc.date.available | 2026-04-16T10:27:10Z | |
| dc.date.created | 2026-03-24 | |
| dc.description.abstract | This research explores (PGM, Co(III)) heterobimetallic complexes as a targeted alternative to traditional Pt(II) therapies like cisplatin, which are often limited by systemic toxicity and drug resistance. The study specifically evaluates KN1 (DTBC), an iron-chelating ligand, and KNK 0.1 (Co(tren)DTBC), a cobalt-based prodrug designed for selective activation. Using two-way ANOVA for data analysis, the drugs were tested against the MCF-7 breast cancer cell line across 24-hour and 72-hour intervals under both normoxic and hypoxic conditions. Results indicated that while KN1 exhibits moderate cytotoxicity, KNK 0.1 effectively functions as a hypoxia-activated anticancer prodrug, releasing its cytotoxic payload specifically in oxygen-deficient environments. Ultimately, this work demonstrates the potential of cobalt-containing complexes to improve tumor selectivity and reduce the side effects typically associated with conventional chemotherapy. | |
| dc.description.course | gyógyszerész | |
| dc.description.courselang | angol | |
| dc.description.degree | egységes, osztatlan | |
| dc.format.extent | 45 | |
| dc.identifier.uri | https://hdl.handle.net/2437/406295 | |
| dc.language.iso | en | |
| dc.rights.info | Hozzáférhető a 2022 decemberi felsőoktatási törvénymódosítás értelmében. | |
| dc.subject | Anticancer methods | |
| dc.subject | Cobalt complex | |
| dc.subject | Hypoxia-activated prodrugs | |
| dc.subject.dspace | Chemistry::Inorganic Chemisty | |
| dc.title | Biological studies of iron chelating agent KN1 and cobalt containing complex KNK 0.1 as hypoxia-activated anticancer prodrugs |
Fájlok
Eredeti köteg (ORIGINAL bundle)
1 - 2 (Összesen 2)
Nincs kép
- Név:
- Thesis-Phan Trung Phuong.docx.pdf
- Méret:
- 4.36 MB
- Formátum:
- Adobe Portable Document Format
- Leírás:
Nincs kép
- Név:
- declaration.pdf
- Méret:
- 126.03 KB
- Formátum:
- Adobe Portable Document Format
- Leírás:
Engedélyek köteg
1 - 1 (Összesen 1)
Nincs kép
- Név:
- license.txt
- Méret:
- 1.94 KB
- Formátum:
- Item-specific license agreed upon to submission
- Leírás: